| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0008-6363(98)00017-0 |
| P698 | PubMed publication ID | 9709410 |
| P50 | author | Keith Fox | Q72227369 |
| P2093 | author name string | C A Ludlam | |
| D E Newby | |||
| D J Webb | |||
| N A Boon | |||
| R A Wright | |||
| P Dawson | |||
| P2860 | cites work | Thrombin stimulates tissue plasminogen activator release from cultured human endothelial cells | Q34621520 |
| Mechanisms of tissue-type plasminogen activator (tPA) clearance by the liver | Q35240629 | ||
| Direct observation of substance P-induced internalization of neurokinin 1 (NK1) receptors at sites of inflammation | Q35756728 | ||
| Effects of NK1 receptor antagonists on vasodilation induced by chemical and electrical activation of sensory C-fibre afferents in different organs | Q36677376 | ||
| Circadian Variation of Fibrinolytic Activity in Blood | Q37054785 | ||
| Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group | Q39522420 | ||
| Prospective study of endogenous tissue plasminogen activator and risk of stroke | Q41036094 | ||
| Endogenous tissue-type plasminogen activator and risk of myocardial infarction | Q41079493 | ||
| Serial angiographic assessment of coronary artery obstruction and collateral flow in acute myocardial infarction. Report from the second Mount Sinai-New York University Reperfusion Trial | Q41262834 | ||
| Effect of NG-monomethyl-L-arginine on kinin-induced vasodilation in the human forearm | Q41836203 | ||
| Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide | Q42435523 | ||
| Complex intracellular signal transduction regulates tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type-1 (PAI-1) synthesis in cultured human umbilical vein endothelium | Q42478859 | ||
| Coronary vascular nitric oxide activity in hypertension and hypercholesterolemia. Comparison of acetylcholine and substance P. | Q42528748 | ||
| Phosphoramidon inhibition of the in vivo conversion of big endothelin-1 to endothelin-1 in the human forearm. | Q42707451 | ||
| Mechanism of endothelium-dependent relaxation induced by substance P in the coronary artery of the pig. | Q42708460 | ||
| Factor VII and fibrinolytic response to deamino-8-D-argenine vasopressin in normal subjects and dissociate response in some patients with haemophilia and von Willebrand's disease | Q45863758 | ||
| Tissue plasminogen activator: Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction | Q49171664 | ||
| Substance P induces biphasic endothelium-dependent relaxations in pig and rabbit carotid arteries. | Q50773475 | ||
| Prevention of coronary thrombosis with subthrombolytic doses of tissue-type plasminogen activator. | Q52657289 | ||
| Measuring forearm blood flow and interpreting the responses to drugs and mediators. | Q54173509 | ||
| Passive Smoking and Impaired Endothelium-Dependent Arterial Dilatation in Healthy Young Adults | Q56428796 | ||
| Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication | Q57791545 | ||
| The involvement of products of the phospholipase pathway in the acute release of tissue-type plasminogen activator from perfused rat hindlegs | Q68040129 | ||
| Impaired release of tissue plasminogen activator (t-PA) following DDAVP infusion in von Willebrand??s disease with low platelet von Willebrand factor content | Q68157200 | ||
| Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications | Q69018269 | ||
| Vasodilatation by calcitonin gene-related peptide and by substance P: a comparison of their effects on resistance and capacitance vessels of human forearms | Q69024497 | ||
| Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction | Q69973450 | ||
| Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function | Q70743346 | ||
| The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis; inefficiency of activators added afterwards | Q70792915 | ||
| Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction | Q71310542 | ||
| Impaired endothelium-dependent vasodilation in patients with essential hypertension: evidence that the abnormality is not at the muscarinic receptor level | Q71625261 | ||
| Impaired endothelium-dependent vascular relaxation in patients with hypercholesterolemia extends beyond the muscarinic receptor | Q71664669 | ||
| Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels | Q73606377 | ||
| P433 | issue | 2 | |
| P921 | main subject | plasminogen | Q107129060 |
| P304 | page(s) | 485-492 | |
| P577 | publication date | 1998-05-01 | |
| P1433 | published in | Cardiovascular Research | Q4642329 |
| P1476 | title | The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man | |
| P478 | volume | 38 |
| Q44283440 | Acute systemic inflammation enhances endothelium-dependent tissue plasminogen activator release in men. |
| Q34514071 | Atherosclerosis, cigarette smoking, and endogenous fibrinolysis: is there a direct link? |
| Q28388398 | Effect of wood smoke exposure on vascular function and thrombus formation in healthy fire fighters |
| Q80738438 | Fibrinolytic markers and vasodilatory capacity following acute exercise among men of differing training status |
| Q28343977 | Hypercholesterolaemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo |
| Q44133527 | Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy |
| Q35771254 | Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease |
| Q34986710 | Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents |
| Q43634793 | The impaired fibrinolytic capacity in hypertension is unaffected by acute blood pressure lowering |
| Q33833244 | Vascular biosynthesis of nitric oxide: effect on hemostasis and fibrinolysis |
| Q34459056 | Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications |
Search more.